Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 64

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 64
---
 not include, as of that date:

| • |     | 6,506,070 shares of Common Stock issuable upon the exercise of stock options outstanding at a weighted exercise 
 price of $5.13 per share;                                                                                       |

S-9

| • |     | 114 shares of Common Stock issuable upon the settlement of restricted stock units outstanding; |

| • |     | 11,841,840 shares of Common Stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity 
 Incentive Plan;                                                                                               |

| • |     | 12,129,635 shares of Common Stock issuable upon the exercise of warrants outstanding at a weighted exercise price 
 of $4.70 per share;                                                                                               |

| • |     | up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the                                                 
 Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Therapeutics, Inc.) and Equiniti Trust Company, LLC; and |

| • |     | up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject             
 to adjustment for certain losses incurred or accrued during the six-month period following the closing of the Kineta Merger. |

To the extent that any of our outstanding options or warrants are exercised, we grant additional options under our stock option plans or issue additional warrants, or we issue additional shares of Common Stock in the future, there may be further dilution to the new investors. S-10

PLAN OF DISTRIBUTION

We have entered into the Sales Agreement, dated as of November 3, 2025, under which we may offer and sell shares of our Common Stock from
time to time through the Sales Agent. Pursuant to this prospectus supplement and the accompanying base prospectus, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to $50,000,000.

The Sales Agreement provides that sales of our Common Stock, if any, under this prospectus supplement may be made in sales deemed to be
“at the market offerings” as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market, or any other existing trading market in the United States for our common